
The company says this feat makes it the first to enable such control without penetrating the brain. Activities achieved included making phone calls, sending messages and playing Mario Kart.
According to Precision, cursor control is widely recognized as a foundational milestone for BCI technology. In recent BCI developments, technology achieved this through access deep in the brain. For instance, Neuralink’s BCI implant achieved real-time cursor control. However, that system relies on electrodes penetrating the brain.
Precision Neuroscience develops the Layer 7 cortical interface system. The high-density, ultra-thin cortical electrode array enables BCI technology that aims to address paralysis. Using AI models, it translates brain activity into a code that can help inform motor function restoration.
Layer 7 features 1,024 electrodes embedded in a flexible film that conforms to the brain surface. It comes in at one-fifth the thickness of a human hair. This device aims to help users with severe paralysis operate digital devices, like computers and smartphones, using their thoughts.
The New York-based company won FDA clearance for Layer 7 in April 2025. It also partnered with Medtronic this year to further advance BCI technology.
Layer 7 sits on top of the brain, causing no damage to tissue. Now, Precision says its milestone proves that powerful BCI functionality is possible without penetrating the brain. The company says that, if these systems don’t damage the brain, they become much more scalable, accessible, and practical for a wide range of potential uses in the future.
Jayme Strauss, chief clinical officer at Precision Neuroscience, said:
“Our goal from day one has been to break down the walls of isolation that come with paralysis. By achieving real-time cursor control completely on the surface of the brain, we’ve proven that we don’t have to compromise safety to achieve high-performance results. This is a thrilling glimpse into the future of BCIs, and we are moving faster than ever to bring this technology to patients who need it most.”
